| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Testosterone | 63 | 2024 | 535 | 6.360 |
Why?
|
| Hormone Replacement Therapy | 27 | 2023 | 196 | 4.590 |
Why?
|
| Hypogonadism | 30 | 2024 | 284 | 3.990 |
Why?
|
| Androgens | 20 | 2018 | 274 | 2.180 |
Why?
|
| Prostatic Neoplasms | 13 | 2023 | 1544 | 1.330 |
Why?
|
| Sexual Behavior | 8 | 2024 | 244 | 1.250 |
Why?
|
| Sexual Dysfunction, Physiological | 8 | 2018 | 78 | 1.200 |
Why?
|
| Erectile Dysfunction | 10 | 2024 | 180 | 1.100 |
Why?
|
| Prostate-Specific Antigen | 7 | 2023 | 256 | 0.970 |
Why?
|
| Cardiovascular Diseases | 13 | 2024 | 1942 | 0.930 |
Why?
|
| Prostatic Hyperplasia | 7 | 2007 | 117 | 0.810 |
Why?
|
| 5-alpha Reductase Inhibitors | 5 | 2007 | 14 | 0.710 |
Why?
|
| Gonadal Steroid Hormones | 3 | 2014 | 88 | 0.710 |
Why?
|
| Andropause | 2 | 2013 | 3 | 0.680 |
Why?
|
| Prostate | 10 | 2023 | 435 | 0.670 |
Why?
|
| Azasteroids | 5 | 2007 | 6 | 0.660 |
Why?
|
| Metabolic Syndrome | 2 | 2015 | 338 | 0.660 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2023 | 1259 | 0.650 |
Why?
|
| Libido | 7 | 2018 | 33 | 0.620 |
Why?
|
| Male | 88 | 2024 | 61018 | 0.580 |
Why?
|
| Aged | 42 | 2024 | 19545 | 0.580 |
Why?
|
| Dihydrotestosterone | 15 | 2007 | 67 | 0.580 |
Why?
|
| Androgen-Binding Protein | 6 | 2007 | 26 | 0.540 |
Why?
|
| Enzyme Inhibitors | 6 | 2007 | 578 | 0.530 |
Why?
|
| Penile Erection | 7 | 2018 | 75 | 0.510 |
Why?
|
| Atrioventricular Node | 1 | 2014 | 18 | 0.470 |
Why?
|
| Hypopituitarism | 1 | 2014 | 17 | 0.470 |
Why?
|
| Pheochromocytoma | 1 | 2014 | 34 | 0.470 |
Why?
|
| Risk Reduction Behavior | 4 | 2013 | 141 | 0.450 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2014 | 67 | 0.450 |
Why?
|
| Hypoglycemic Agents | 3 | 2013 | 440 | 0.440 |
Why?
|
| Double-Blind Method | 13 | 2023 | 1630 | 0.440 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2014 | 118 | 0.440 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2014 | 109 | 0.430 |
Why?
|
| Testis | 7 | 2008 | 409 | 0.410 |
Why?
|
| Shock, Cardiogenic | 1 | 2014 | 192 | 0.410 |
Why?
|
| Pacemaker, Artificial | 1 | 2014 | 174 | 0.400 |
Why?
|
| Diabetic Angiopathies | 1 | 2013 | 65 | 0.400 |
Why?
|
| Preventive Health Services | 1 | 2013 | 60 | 0.390 |
Why?
|
| Catheter Ablation | 1 | 2014 | 236 | 0.390 |
Why?
|
| Hyperglycemia | 1 | 2013 | 222 | 0.380 |
Why?
|
| Motor Activity | 1 | 2014 | 509 | 0.380 |
Why?
|
| Humans | 78 | 2024 | 124227 | 0.360 |
Why?
|
| Blood Glucose | 3 | 2013 | 1135 | 0.360 |
Why?
|
| Heart Arrest | 1 | 2014 | 351 | 0.340 |
Why?
|
| Receptors, Androgen | 7 | 2003 | 413 | 0.340 |
Why?
|
| Coronary Artery Bypass | 1 | 2013 | 513 | 0.330 |
Why?
|
| Middle Aged | 33 | 2024 | 26605 | 0.320 |
Why?
|
| Estradiol | 8 | 2004 | 535 | 0.320 |
Why?
|
| Androgen Antagonists | 5 | 2004 | 119 | 0.310 |
Why?
|
| Cardiovascular System | 2 | 2021 | 105 | 0.310 |
Why?
|
| Gels | 8 | 2023 | 69 | 0.300 |
Why?
|
| Treatment Outcome | 12 | 2021 | 12272 | 0.290 |
Why?
|
| Apoptosis | 5 | 2007 | 1784 | 0.290 |
Why?
|
| Sex Hormone-Binding Globulin | 6 | 2011 | 40 | 0.280 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2007 | 47 | 0.280 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2007 | 100 | 0.280 |
Why?
|
| Estrenes | 1 | 2006 | 21 | 0.260 |
Why?
|
| Transgenes | 1 | 2007 | 334 | 0.260 |
Why?
|
| Cell Division | 1 | 2007 | 776 | 0.250 |
Why?
|
| Walking | 2 | 2018 | 159 | 0.250 |
Why?
|
| Caspases | 3 | 2000 | 162 | 0.230 |
Why?
|
| Endocrinology | 2 | 2018 | 134 | 0.230 |
Why?
|
| Risk Assessment | 8 | 2016 | 3428 | 0.230 |
Why?
|
| Aging | 7 | 2018 | 1166 | 0.220 |
Why?
|
| Urinary Retention | 1 | 2023 | 18 | 0.220 |
Why?
|
| Organ Size | 7 | 2003 | 425 | 0.210 |
Why?
|
| Surveys and Questionnaires | 4 | 2018 | 3688 | 0.210 |
Why?
|
| Finasteride | 4 | 1997 | 20 | 0.210 |
Why?
|
| Prostatic Diseases | 1 | 2003 | 15 | 0.210 |
Why?
|
| Pregnanes | 2 | 1994 | 5 | 0.210 |
Why?
|
| Obesity | 3 | 2011 | 2262 | 0.200 |
Why?
|
| Bone Density | 3 | 2017 | 318 | 0.200 |
Why?
|
| Adult | 25 | 2017 | 29367 | 0.200 |
Why?
|
| Coronary Artery Disease | 2 | 2020 | 771 | 0.190 |
Why?
|
| Luteinizing Hormone | 12 | 2006 | 131 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2023 | 6465 | 0.190 |
Why?
|
| Administration, Cutaneous | 5 | 2017 | 66 | 0.190 |
Why?
|
| Postoperative Complications | 1 | 2013 | 3058 | 0.190 |
Why?
|
| Mobility Limitation | 2 | 2018 | 23 | 0.180 |
Why?
|
| Germ-Line Mutation | 1 | 2003 | 332 | 0.180 |
Why?
|
| Progesterone | 2 | 2003 | 624 | 0.180 |
Why?
|
| Orchiectomy | 4 | 2007 | 49 | 0.180 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 1322 | 0.180 |
Why?
|
| Lovastatin | 2 | 1998 | 27 | 0.180 |
Why?
|
| DNA | 6 | 2006 | 1595 | 0.180 |
Why?
|
| Risk | 2 | 2013 | 754 | 0.170 |
Why?
|
| Follicle Stimulating Hormone | 9 | 2004 | 186 | 0.160 |
Why?
|
| Placebos | 2 | 2016 | 240 | 0.150 |
Why?
|
| Urology | 1 | 2000 | 75 | 0.150 |
Why?
|
| Prognosis | 3 | 2019 | 4608 | 0.150 |
Why?
|
| Body Composition | 3 | 2015 | 522 | 0.150 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2018 | 12 | 0.150 |
Why?
|
| Cyproterone Acetate | 3 | 1994 | 8 | 0.150 |
Why?
|
| Fatigue | 2 | 2016 | 185 | 0.150 |
Why?
|
| Quality of Life | 3 | 2017 | 1897 | 0.140 |
Why?
|
| Adenoviridae | 1 | 2000 | 605 | 0.140 |
Why?
|
| Sleep, REM | 1 | 1997 | 25 | 0.140 |
Why?
|
| Hemoglobins | 2 | 2017 | 303 | 0.140 |
Why?
|
| Receptors, Steroid | 4 | 1988 | 275 | 0.140 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 4344 | 0.140 |
Why?
|
| Risk Factors | 6 | 2016 | 10239 | 0.130 |
Why?
|
| Spinal Fractures | 1 | 2017 | 39 | 0.130 |
Why?
|
| Rats | 13 | 1995 | 3676 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2014 | 3411 | 0.130 |
Why?
|
| Lumbar Vertebrae | 1 | 2017 | 113 | 0.130 |
Why?
|
| Vascular Calcification | 1 | 2017 | 56 | 0.130 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2016 | 31 | 0.130 |
Why?
|
| Hip Fractures | 1 | 2017 | 61 | 0.130 |
Why?
|
| Biomarkers | 5 | 2020 | 3049 | 0.130 |
Why?
|
| Speech Recognition Software | 1 | 2015 | 4 | 0.130 |
Why?
|
| Consensus | 2 | 2018 | 640 | 0.130 |
Why?
|
| Seminal Vesicles | 2 | 2007 | 55 | 0.130 |
Why?
|
| Stromal Cells | 1 | 1997 | 299 | 0.120 |
Why?
|
| Androstenedione | 1 | 1995 | 11 | 0.120 |
Why?
|
| Peptide Hormones | 2 | 2006 | 68 | 0.120 |
Why?
|
| Adrenalectomy | 1 | 2014 | 37 | 0.120 |
Why?
|
| Contraceptive Agents, Male | 3 | 2006 | 27 | 0.120 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5127 | 0.120 |
Why?
|
| Gait | 1 | 2014 | 83 | 0.120 |
Why?
|
| Aromatase Inhibitors | 1 | 1995 | 76 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2017 | 236 | 0.120 |
Why?
|
| Disability Evaluation | 1 | 2015 | 190 | 0.110 |
Why?
|
| Clinical Trials as Topic | 3 | 2018 | 1086 | 0.110 |
Why?
|
| Impotence, Vasculogenic | 1 | 2013 | 10 | 0.110 |
Why?
|
| Insulin | 5 | 2013 | 1200 | 0.110 |
Why?
|
| Pituitary Gland | 2 | 2008 | 82 | 0.110 |
Why?
|
| Sleep | 2 | 1995 | 339 | 0.110 |
Why?
|
| Androstenes | 1 | 1993 | 6 | 0.110 |
Why?
|
| Young Adult | 3 | 2017 | 8999 | 0.110 |
Why?
|
| Hydrocortisone | 4 | 1990 | 217 | 0.100 |
Why?
|
| Secretoglobins | 4 | 1995 | 4 | 0.100 |
Why?
|
| Prostatein | 4 | 1995 | 4 | 0.100 |
Why?
|
| Anemia | 1 | 2017 | 339 | 0.100 |
Why?
|
| Muscle, Skeletal | 3 | 2006 | 942 | 0.100 |
Why?
|
| Drug Delivery Systems | 2 | 2004 | 186 | 0.100 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2013 | 29 | 0.100 |
Why?
|
| Uteroglobin | 4 | 1995 | 45 | 0.100 |
Why?
|
| Life Expectancy | 1 | 2013 | 53 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2003 | 3152 | 0.100 |
Why?
|
| Postoperative Period | 1 | 2013 | 330 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2015 | 1103 | 0.100 |
Why?
|
| Female | 11 | 2015 | 66301 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 2142 | 0.100 |
Why?
|
| Animals | 18 | 2007 | 34067 | 0.100 |
Why?
|
| Regeneration | 1 | 1994 | 197 | 0.100 |
Why?
|
| Veterans | 1 | 2003 | 1752 | 0.100 |
Why?
|
| RNA, Messenger | 4 | 1998 | 2815 | 0.100 |
Why?
|
| Steroids | 2 | 1984 | 202 | 0.090 |
Why?
|
| Insulin Resistance | 2 | 2015 | 637 | 0.090 |
Why?
|
| United States | 5 | 2018 | 10874 | 0.090 |
Why?
|
| Affect | 2 | 2004 | 153 | 0.090 |
Why?
|
| Physician's Role | 1 | 2013 | 164 | 0.090 |
Why?
|
| Acid Phosphatase | 2 | 1991 | 13 | 0.090 |
Why?
|
| Patient Selection | 1 | 2015 | 688 | 0.090 |
Why?
|
| Weight Loss | 1 | 2015 | 480 | 0.090 |
Why?
|
| Mice, Transgenic | 2 | 2007 | 2392 | 0.090 |
Why?
|
| Dutasteride | 2 | 2007 | 4 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 2084 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2013 | 1251 | 0.090 |
Why?
|
| Research Design | 1 | 2014 | 689 | 0.080 |
Why?
|
| Time Factors | 4 | 2017 | 6275 | 0.080 |
Why?
|
| Appetite | 2 | 2006 | 37 | 0.080 |
Why?
|
| Incidence | 3 | 2013 | 3132 | 0.080 |
Why?
|
| Electrocardiography | 1 | 2014 | 968 | 0.080 |
Why?
|
| Ghrelin | 2 | 2006 | 53 | 0.080 |
Why?
|
| Diabetes Mellitus | 2 | 2013 | 853 | 0.080 |
Why?
|
| Serum Albumin | 2 | 2006 | 110 | 0.080 |
Why?
|
| Rats, Inbred Strains | 4 | 1991 | 232 | 0.080 |
Why?
|
| Men | 1 | 2008 | 4 | 0.080 |
Why?
|
| Age Distribution | 2 | 2013 | 414 | 0.080 |
Why?
|
| Hospital Mortality | 1 | 2013 | 1020 | 0.080 |
Why?
|
| Estrogens | 4 | 1986 | 514 | 0.080 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2007 | 4 | 0.070 |
Why?
|
| Flutamide | 2 | 2003 | 26 | 0.070 |
Why?
|
| Disease Progression | 3 | 2020 | 2044 | 0.070 |
Why?
|
| Reference Values | 4 | 2017 | 711 | 0.070 |
Why?
|
| Drug Administration Routes | 2 | 2017 | 32 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2006 | 340 | 0.070 |
Why?
|
| Signal Transduction | 1 | 1999 | 4503 | 0.070 |
Why?
|
| Interleukin-6 | 2 | 2006 | 419 | 0.070 |
Why?
|
| Prevalence | 2 | 2004 | 2445 | 0.070 |
Why?
|
| Castration | 2 | 1995 | 33 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1995 | 1231 | 0.070 |
Why?
|
| Hypothalamus | 1 | 2008 | 221 | 0.070 |
Why?
|
| Triamcinolone Acetonide | 2 | 1978 | 37 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2006 | 680 | 0.070 |
Why?
|
| Registries | 3 | 2017 | 1422 | 0.060 |
Why?
|
| Caspase 7 | 3 | 2000 | 9 | 0.060 |
Why?
|
| Ovulation | 2 | 1978 | 109 | 0.060 |
Why?
|
| Mice | 4 | 2007 | 17627 | 0.060 |
Why?
|
| Drug Monitoring | 2 | 2017 | 171 | 0.060 |
Why?
|
| Cachexia | 1 | 2005 | 47 | 0.060 |
Why?
|
| Bone Remodeling | 2 | 2004 | 55 | 0.060 |
Why?
|
| Cheek | 1 | 2004 | 26 | 0.060 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2004 | 1 | 0.060 |
Why?
|
| Evidence-Based Medicine | 3 | 2018 | 633 | 0.060 |
Why?
|
| Binding, Competitive | 3 | 1995 | 185 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2007 | 616 | 0.060 |
Why?
|
| Staurosporine | 2 | 2000 | 23 | 0.050 |
Why?
|
| Transdermal Patch | 1 | 2023 | 8 | 0.050 |
Why?
|
| Epidemiologic Studies | 1 | 2003 | 43 | 0.050 |
Why?
|
| Caspase 2 | 2 | 2000 | 28 | 0.050 |
Why?
|
| Caspase 3 | 2 | 2000 | 132 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2003 | 252 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2018 | 690 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2004 | 204 | 0.050 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 371 | 0.050 |
Why?
|
| Age Factors | 2 | 2006 | 2808 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2000 | 3038 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2003 | 707 | 0.050 |
Why?
|
| Prolactin | 3 | 1979 | 114 | 0.050 |
Why?
|
| Spermatogenesis | 2 | 1979 | 171 | 0.040 |
Why?
|
| Endothelium, Vascular | 2 | 2013 | 520 | 0.040 |
Why?
|
| Cholesterol | 3 | 2000 | 536 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2000 | 125 | 0.040 |
Why?
|
| Lac Operon | 1 | 2000 | 95 | 0.040 |
Why?
|
| Adolescent | 2 | 2017 | 19260 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2004 | 1689 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2861 | 0.040 |
Why?
|
| Drug Administration Schedule | 4 | 2004 | 721 | 0.040 |
Why?
|
| Skin | 1 | 1983 | 517 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2000 | 311 | 0.040 |
Why?
|
| Pedigree | 1 | 2003 | 1605 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2007 | 1533 | 0.040 |
Why?
|
| Anthropometry | 1 | 2020 | 197 | 0.040 |
Why?
|
| Kinetics | 2 | 1997 | 1323 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 2000 | 461 | 0.040 |
Why?
|
| Carrier Proteins | 3 | 1979 | 1022 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2006 | 3268 | 0.040 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2020 | 122 | 0.040 |
Why?
|
| Walk Test | 1 | 2018 | 23 | 0.040 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2018 | 3 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2018 | 71 | 0.040 |
Why?
|
| Cytoplasm | 1 | 1979 | 290 | 0.040 |
Why?
|
| Monitoring, Physiologic | 2 | 2010 | 356 | 0.040 |
Why?
|
| Blood Chemical Analysis | 1 | 2018 | 80 | 0.040 |
Why?
|
| Growth Hormone | 3 | 1990 | 150 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 1 | 1998 | 114 | 0.040 |
Why?
|
| Mevalonic Acid | 1 | 1997 | 19 | 0.040 |
Why?
|
| Leuprolide | 1 | 1997 | 22 | 0.030 |
Why?
|
| Adenoma, Chromophobe | 1 | 1977 | 2 | 0.030 |
Why?
|
| Mass Screening | 1 | 2003 | 781 | 0.030 |
Why?
|
| Diterpenes | 1 | 1997 | 28 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 64 | 0.030 |
Why?
|
| Sample Size | 1 | 2017 | 86 | 0.030 |
Why?
|
| Cyproterone | 2 | 1987 | 4 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2017 | 177 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2000 | 940 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 353 | 0.030 |
Why?
|
| Polysomnography | 1 | 1997 | 145 | 0.030 |
Why?
|
| Executive Function | 1 | 2017 | 110 | 0.030 |
Why?
|
| Pituitary Neoplasms | 1 | 1977 | 80 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 299 | 0.030 |
Why?
|
| Mental Recall | 1 | 2017 | 143 | 0.030 |
Why?
|
| Voice | 1 | 2015 | 14 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 1010 | 0.030 |
Why?
|
| Insulin, Isophane | 1 | 1995 | 1 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2013 | 16276 | 0.030 |
Why?
|
| Drug Labeling | 1 | 2015 | 27 | 0.030 |
Why?
|
| Stroke | 1 | 2023 | 976 | 0.030 |
Why?
|
| Anticholesteremic Agents | 1 | 1998 | 234 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 149 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 1997 | 797 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2017 | 425 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2015 | 275 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 1999 | 678 | 0.030 |
Why?
|
| Osmolar Concentration | 2 | 2004 | 176 | 0.030 |
Why?
|
| Ankle Brachial Index | 1 | 2013 | 40 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2015 | 372 | 0.030 |
Why?
|
| Calcium | 2 | 2013 | 1100 | 0.030 |
Why?
|
| General Practice | 1 | 2013 | 7 | 0.030 |
Why?
|
| Memory | 1 | 2017 | 363 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2013 | 74 | 0.030 |
Why?
|
| Random Allocation | 1 | 1994 | 436 | 0.030 |
Why?
|
| Proteins | 2 | 1994 | 1036 | 0.030 |
Why?
|
| Cell Count | 1 | 1993 | 252 | 0.030 |
Why?
|
| Sleep Stages | 2 | 1990 | 32 | 0.020 |
Why?
|
| Cognition | 1 | 2017 | 710 | 0.020 |
Why?
|
| Adenoma, Islet Cell | 1 | 1971 | 8 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2012 | 83 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 1367 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2012 | 168 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1971 | 126 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2017 | 6121 | 0.020 |
Why?
|
| Epithelium | 1 | 1991 | 362 | 0.020 |
Why?
|
| RNA | 1 | 1994 | 570 | 0.020 |
Why?
|
| Neoplasms | 1 | 2005 | 2763 | 0.020 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1990 | 37 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 1997 | 731 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1990 | 107 | 0.020 |
Why?
|
| Culture Techniques | 1 | 1990 | 89 | 0.020 |
Why?
|
| Schistosomiasis | 1 | 1990 | 50 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1990 | 260 | 0.020 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 1990 | 39 | 0.020 |
Why?
|
| Life Style | 1 | 2012 | 406 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 1990 | 258 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2013 | 537 | 0.020 |
Why?
|
| Patient Compliance | 2 | 2004 | 468 | 0.020 |
Why?
|
| Scrotum | 1 | 1989 | 24 | 0.020 |
Why?
|
| Hematocrit | 2 | 2004 | 111 | 0.020 |
Why?
|
| Structure-Activity Relationship | 2 | 1981 | 575 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 1998 | 1650 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2012 | 542 | 0.020 |
Why?
|
| Genitalia, Male | 1 | 1988 | 38 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 4779 | 0.020 |
Why?
|
| Genetic Markers | 1 | 1990 | 604 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 1529 | 0.020 |
Why?
|
| Cardiology | 1 | 2013 | 503 | 0.020 |
Why?
|
| Syndrome | 1 | 2010 | 1118 | 0.020 |
Why?
|
| Depression | 1 | 2016 | 1215 | 0.020 |
Why?
|
| Liver | 2 | 1995 | 1736 | 0.020 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 1978 | 80 | 0.020 |
Why?
|
| Alkaline Phosphatase | 2 | 2001 | 97 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 728 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 1999 | 622 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 1999 | 1059 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2001 | 1010 | 0.020 |
Why?
|
| HIV Infections | 2 | 2010 | 1891 | 0.020 |
Why?
|
| Cholesterol, HDL | 2 | 2000 | 358 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2013 | 911 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 1986 | 155 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1264 | 0.020 |
Why?
|
| Peptide YY | 1 | 2005 | 19 | 0.020 |
Why?
|
| Cholesterol, LDL | 2 | 2000 | 567 | 0.010 |
Why?
|
| Body Mass Index | 2 | 2004 | 1556 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1990 | 1881 | 0.010 |
Why?
|
| Tissue Adhesives | 1 | 2004 | 36 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 52 | 0.010 |
Why?
|
| Chemistry | 1 | 1984 | 60 | 0.010 |
Why?
|
| Hirsutism | 1 | 1984 | 20 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 1984 | 85 | 0.010 |
Why?
|
| Acne Vulgaris | 1 | 1984 | 21 | 0.010 |
Why?
|
| Puberty, Precocious | 1 | 1984 | 26 | 0.010 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 1984 | 91 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2006 | 380 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 1990 | 831 | 0.010 |
Why?
|
| Body Weight | 2 | 1995 | 995 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1988 | 1017 | 0.010 |
Why?
|
| Procollagen | 1 | 2001 | 13 | 0.010 |
Why?
|
| Osteocalcin | 1 | 2001 | 42 | 0.010 |
Why?
|
| Binding Sites | 2 | 1981 | 1295 | 0.010 |
Why?
|
| Phosphorus | 1 | 2001 | 56 | 0.010 |
Why?
|
| Collagen Type I | 1 | 2001 | 112 | 0.010 |
Why?
|
| Biological Availability | 1 | 2000 | 135 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 418 | 0.010 |
Why?
|
| Glucose Tolerance Test | 2 | 1990 | 208 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1981 | 970 | 0.010 |
Why?
|
| Heptanoates | 1 | 1979 | 1 | 0.010 |
Why?
|
| Collagen | 1 | 2001 | 315 | 0.010 |
Why?
|
| Sperm Count | 1 | 1979 | 78 | 0.010 |
Why?
|
| Creatinine | 1 | 2001 | 389 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 931 | 0.010 |
Why?
|
| Ketosteroids | 1 | 1979 | 3 | 0.010 |
Why?
|
| Methane | 1 | 1979 | 13 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 1999 | 17 | 0.010 |
Why?
|
| Sertoli Cells | 1 | 1979 | 78 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 1999 | 32 | 0.010 |
Why?
|
| Spermatocytes | 1 | 1978 | 23 | 0.010 |
Why?
|
| Spermatids | 1 | 1978 | 25 | 0.010 |
Why?
|
| Butyrates | 1 | 1999 | 35 | 0.010 |
Why?
|
| Gamma Rays | 1 | 1978 | 49 | 0.010 |
Why?
|
| Epididymis | 1 | 1979 | 55 | 0.010 |
Why?
|
| beta-Lipotropin | 1 | 1978 | 1 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1983 | 882 | 0.010 |
Why?
|
| Spermatogonia | 1 | 1978 | 33 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1986 | 1011 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1978 | 76 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1999 | 172 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1998 | 46 | 0.010 |
Why?
|
| Clomiphene | 1 | 1978 | 12 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1998 | 54 | 0.010 |
Why?
|
| Progestins | 1 | 1978 | 48 | 0.010 |
Why?
|
| Spermatozoa | 1 | 1979 | 224 | 0.010 |
Why?
|
| Menstruation | 1 | 1978 | 29 | 0.010 |
Why?
|
| Peptides | 1 | 2001 | 794 | 0.010 |
Why?
|
| Hypertrophy | 1 | 1978 | 102 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 1998 | 60 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 1978 | 77 | 0.010 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 1977 | 10 | 0.010 |
Why?
|
| Levodopa | 1 | 1977 | 91 | 0.010 |
Why?
|
| Pyrazoles | 1 | 1979 | 306 | 0.010 |
Why?
|
| Cholesterol, VLDL | 1 | 1995 | 15 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1998 | 1102 | 0.010 |
Why?
|
| C-Peptide | 1 | 1995 | 113 | 0.010 |
Why?
|
| Fasting | 1 | 1995 | 298 | 0.010 |
Why?
|
| Models, Biological | 1 | 1978 | 1455 | 0.010 |
Why?
|
| Triglycerides | 1 | 1995 | 574 | 0.010 |
Why?
|
| Sulfobromophthalein | 1 | 1971 | 3 | 0.010 |
Why?
|
| Tolbutamide | 1 | 1971 | 6 | 0.010 |
Why?
|
| Specific Gravity | 1 | 1971 | 4 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1971 | 81 | 0.010 |
Why?
|
| Urine | 1 | 1971 | 90 | 0.010 |
Why?
|
| Chlorides | 1 | 1971 | 106 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1971 | 250 | 0.010 |
Why?
|
| Glucose | 1 | 1995 | 880 | 0.010 |
Why?
|
| Potassium | 1 | 1971 | 280 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 1971 | 274 | 0.010 |
Why?
|
| Leucine | 1 | 1971 | 311 | 0.010 |
Why?
|
| Sodium | 1 | 1971 | 295 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1995 | 1351 | 0.010 |
Why?
|
| Body Height | 1 | 1990 | 215 | 0.000 |
Why?
|
| Antigen-Antibody Complex | 1 | 1988 | 65 | 0.000 |
Why?
|
| Growth Disorders | 1 | 1990 | 208 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1988 | 390 | 0.000 |
Why?
|
| Cross Reactions | 1 | 1988 | 192 | 0.000 |
Why?
|
| Arginine | 1 | 1990 | 332 | 0.000 |
Why?
|
| Species Specificity | 1 | 1988 | 549 | 0.000 |
Why?
|
| Epitopes | 1 | 1988 | 432 | 0.000 |
Why?
|
| Circadian Rhythm | 1 | 1983 | 272 | 0.000 |
Why?
|
| Metyrapone | 1 | 1978 | 1 | 0.000 |
Why?
|
| 17-Ketosteroids | 1 | 1978 | 4 | 0.000 |
Why?
|
| Lypressin | 1 | 1978 | 16 | 0.000 |
Why?
|
| Thyrotropin | 1 | 1978 | 57 | 0.000 |
Why?
|
| Hypophysectomy | 1 | 1978 | 20 | 0.000 |
Why?
|